NCT01458938

This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.

Substance P Neuropeptide Levels in Saliva, Serum and Cerebrospinal Fluid in Patients With Spinal Disease: A Pilot Study

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 53 (actual)
• Sponsor: Carolina Neurosurgery & Spine Associates · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The objective of this pilot study is to determine if degenerative spinal disorders such as acute radiculopathy, myelopathy, stenosis, or disc and facet disease cause detectable alterations in Substance P levels in saliva, serum and cerebrospinal fluid. If this pilot study shows a correlation between Substance P levels and pain associated with degenerative spinal disorders, then a larger study will be initiated to determine the feasibility of using Substance P levels in the diagnosis and treatment of degenerative spinal disease.

Conditions

• Spinal Disease
• Spinal Radiculopathy
• Myelopathy
• Neurogenic Claudication

Interventions

Type	Name	Description
OTHER	treatment plan	Data Collection Study

Timeline

• Start date: 2009-07-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2011-10-25
• Last updated: 2017-02-01

Locations

1 site across 1 country: United States